The AI lab for RNA medicines
RINAE.AI
An automated platform for genetic disease treatments at scale — from genetic signal to drug design in minutes.
Identify the target. Score multi-modality amenability. Design molecules with predictive efficacy and toxicity.
Example workspace — illustrative, not a real analysis. The findings below are sample data, not a RINAE-produced result.
Argus ◉ pulling evidence from 15 bioinformatics sources — ClinVar, gnomAD, GTEx, OMIM…
The Problem
Genetic disease drug development is fundamentally broken.
Conventional drug development is unrepeatable, unautomated, and too expensive. Consequently, most genetic diseases can never be treated — even though the technology exists.
The brutal math
400M
People living with rare disease
A population the size of a continent, spread across thousands of conditions.
90%
Have no approved treatment
The overwhelming majority of genetic diseases have nothing on the shelf.
10%
Chance any drug program succeeds
Even when a program starts, the odds are stacked against it.
The Mission. RINAE.AI solves this by automating the system end to end — from genetic signal to a treated patient.
The Solution
Three tools. One surface.
Each stage is a real service the team ships today. The platform wires them into one automated, connected workflow with shared state, review gates, and an audit trail.
Stage 1Argus
Pull evidence.
Query 15+ bioinformatics databases for a gene target — expression, variants, constraint, pathways — and materialize one normalized evidence packet.
Stage 2Admiral
Score amenability.
Multi-agent amenability scoring across modalities: specialist models weigh whether the target is treatable and produce a structured report.
Stage 3Metamorph
Design RNA medicines.
Generates antisense oligonucleotide and siRNA candidates with predictive efficacy and toxicity across many design parameters.
“My daughter Rose was diagnosed with HNRNPH2 when she was three. We started RINAE to scale genetic medicines because Rose and millions of others couldn’t wait for the industry to care.”
Casey McPherson
Founder · AlphaRose Therapeutics
Powered by highly connected, AI-ready databases.
Reference corpus
188K ASO patents
ASO Atlas: 417 distinct chemical designs distilled into Admiral's reasoning.
Why we exist
Built to make all genetic disease treatments economically possible.
One workflow
From genetic signal to a designed candidate — one connected workflow instead of fragmented, vendor-by-vendor handoffs.